Valneva issues press release after FDA and CDC recommended pausing use of Chikungunya vaccine IXCHIQ for elderly individuals due to ongoing investigations into reported adverse events (€2.83, 0.00)
FDA and CDC recommend pause in use of Chikungunya vaccine Ixchiq for individuals age 60 and older (€2.83, 0.00)
StreetAccount Summary - Trading higher/lower: EU mid-morning
StreetAccount Summary - European pre-market trading update
Bavarian Nordic A/S reports Q1 net income DKK218.8M vs year-ago (DKK114.5M); FY25 financial guidance is maintained (DKK 155.10, 0.00)
Bavarian Nordic awarded $143.6M contract options from US Government for production and supply of freeze-dried smallpox/Mpox vaccines; FY25 financial guidance remains unchanged (DKK 158.45, 0.00)
EMA's PRAC and ETF comment on the safety of Ixchiq (€2.91, 0.00)
Bavarian Nordic A/S receives marketing authorization from MHRA in UK for VIMKUNYA for active immunization for prevention of disease caused by chikungunya virus in individuals 12 years and older (DKK 156.85, 0.00)
StreetAccount Sector Summary - Healthcare Pre-Market
StreetAccount Sector Summary - Healthcare Post-Market
Powered by FactSet Research Systems Inc.